Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.

Name: Kaimen Rigor review — Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.
Item: Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.
Rating: 96
Author: Alpha1

Sarraju A, Brennan D, Hayden K, Stronczek A, Goldberg AC, Michos ED, McGuire DK, Mason D, Tercek G, Nicholls SJ, Kling D, Neild AL, Kastelein J, Davidson M, Ditmarsch M, Nissen SE

Paper source

Read full text

Embed this Rigor badge

Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.

Sarraju A, Brennan D, Hayden K, Stronczek A, Goldberg AC, Michos ED, McGuire DK, Mason D, Tercek G, Nicholls SJ, Kling D, Neild AL, Kastelein J, Davidson M, Ditmarsch M, Nissen SE

Read full text

DOI

10.1016/S0140-6736(25)00721-4

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/7dafeffa-3328-45df-a199-bb707f5f8678" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/7dafeffa-3328-45df-a199-bb707f5f8678/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

4e44c43e2290da7abfb40178a7413165bcb6bac820c4bf1f10aedb05e5cd16d7

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.

Sarraju A, Brennan D, Hayden K, Stronczek A, Goldberg AC, Michos ED, McGuire DK, Mason D, Tercek G, Nicholls SJ, Kling D, Neild AL, Kastelein J, Davidson M, Ditmarsch M, Nissen SE

Paper source

Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.

Read full text

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 17 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on LDL cholesterol reduction, a surrogate biomarker for cardiovascular outcomes. Although the paper cites prior evidence linking LDL cholesterol reduction to reduced ASCVD events, it does not demonstrate target engagement (e.g., PK/PD) at the tested dose in this trial, and the surrogate-to-clinical-outcome link is not validated within this study. The claim of clinical benefit is inferred from LDL lowering.
“Combination therapy of obicetrapib and ezetimibe significantly reduced LDL cholesterol. This oral, single-pill therapy could improve LDL cholesterol management in patients with pre-existing or high risk for ASCVD.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit4 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported Phase 3 randomized controlled trial with rigorous design, clear ethics approvals, and appropriate statistical methods. The main weaknesses are a vague data availability statement and minor reporting inconsistencies (e.g., missing explicit CONSORT reference, CI sign inconsistency in abstract).

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence to reconcile. The study is a human interventional trial, so several sub-criteria (e.g., replicate distinction, controls, species/strain, housing, IACUC) are not applicable. The statistics verification recomputed 8 reported tests consistently, but this does not confirm all statistical results; the citation check found no retracted or unresolved references.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 8 tests: 8 consistent, 0 inconsistent; 8 via agent-written checks.

Overstated conclusions

1 finding · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior trials of LDL-lowering drugs and a meta-analysis of statin trials, and discusses the unmet need for oral therapies. The rationale for the FDC is based on prior phase 2 studies of obicetrapib and ezetimibe. Limitations of prior CETP inhibitor trials are acknowledged, and the study design addresses some of these.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

“Clinical trials of several classes of LDL cholesterol-lowering drugs have shown consistent reductions in major adverse cardiovascular events.”

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 2]

“Obicetrapib is an orally administered, selective CETP inhibitor that significantly reduced LDL cholesterol in small phase 2 studies in participants without ASCVD when administered as monotherapy or in combination with ezetimibe.”

paraphrase[Discussion, paragraph 4]

“In the first phase 3 cardiovascular outcome trial of a CETP inhibitor, treatment with torcetrapib increased morbidity and mortality, most likely as a consequence of off-target toxicity attributed to an aldosterone-like effect with an increase in systolic blood pressure of 5·4 mm Hg.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 1]

“A large meta-analysis of statin drug trials demonstrated a 22% reduction in cardiovascular events for each 1 mmol/L (38·7 mg/dL) reduction in LDL cholesterol concentration.”

paraphrase[Introduction, paragraph 2]

“ROSE2 was a randomised phase 2 trial of obicetrapib plus ezetimibe for LDL cholesterol reduction, and provided initial data regarding the LDL cholesterol-lowering efficacy of obicetrapib plus ezetimibe in 97 patients with dyslipidaemia.”

Research in contextFind in source

Randomization was computer-generated with a permuted block design, and blinding was achieved with identical tablets/capsules. A power analysis was performed with a sample size of 95 per group. Inclusion/exclusion criteria were pre-specified. The analysis population (ITT) and missing data imputation were defined. The trial is a human RCT, so replicate_distinction, controls, and independent_replication are not applicable.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomisation and masking]

“Randomisation was computer-generated by a contract research organisation through the ClinTrak Interactive Response Technology system. A permuted block design was used (block size of 8).”

“Masking was achieved by the use of identical tablets and capsules such that study investigators and participants could not determine whether they contained active drug or placebo.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

“Assuming a standard deviation of 25% at a one-sided significance level of 0·025, a sample size of 95 participants per treatment group (380 total) was estimated to provide more than 90% power to detect a 30% difference in LDL cholesterol reduction for the FDC treatment group compared with the placebo group”

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomisation and masking]

“Randomisation was computer-generated by a contract research organisation through the ClinTrak Interactive Response Technology system. A permuted block design was used (block size of 8).”

“Participants, investigators, academic leadership, the contract research organisation, and the sponsor were masked to treatment allocation and all lipid results during the trial until all study-related visits and assessments were completed and the database was locked.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

The paper reports sex, age, race, ethnicity, and comorbidities in Table 1. Both sexes are enrolled, so sex_justified is not applicable. Age and health status are reported. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline characteristics are well reported, including sex, age, and health status.

Evidence

paraphrase[Results, paragraph 1]

“The median age of participants was 68·0 years (IQR 62·0–73·0), 79 (19%) were at least 75 years of age, 177 (43%) were female”

paraphrase[Table 1]

“Race: White 86 (84%) ... Black or African American 14 (14%) ... Ethnicity: Hispanic or Latino 4 (4%)”

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, race, and comorbidities.

Evidence

paraphrase[Table 1]

“Median age (IQR), years 68·0 (63·0–72·0) 67·0 (61·0–74·0) 68·0 (64·0–73·0) 67·5 (62·0–72·0) Sex Female 48 (47%) 33 (32%) 45 (45%) 51 (50%)”

“Race White 86 (84%) 85 (83%) 82 (81%) 84 (82%) Black or African American 14 (14%) 15 (15%) 13 (13%) 17 (17%)”

Table 1Find in source

“History of ASCVD 72 (71%) 76 (75%) 67 (66%) 65 (64%)”

Table 1Find in source

The protocol was approved by a named central ethics committee (Advarra) with a reference number. Written informed consent was obtained from all participants. The study was conducted in accordance with the Declaration of Helsinki.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval and informed consent are adequately reported.

Evidence

“The protocol and amendments were approved by a central ethics committee (Advarra) for all sites, with initial approval on Sept 28, 2023 (trial reference number Pro00074209).”

MethodsFind in source

“All participants provided written informed consent before undergoing any study procedures.”

MethodsFind in source

“This study was conducted in accordance with ethical principles derived from the Declaration of Helsinki and international ethical guidelines from the Council for International Organizations of Medical Sciences.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval and informed consent are clearly documented.

Evidence

“The protocol and amendments were approved by a central ethics committee (Advarra) for all sites, with initial approval on Sept 28, 2023 (trial reference number Pro00074209).”

MethodsFind in source

“All participants provided written informed consent before undergoing any study procedures.”

MethodsFind in source

The drugs are named with doses and regimen. The statistical software (SAS version 9.4) is identified. No antibodies, cell lines, or other bench reagents are used, so those criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (obicetrapib and ezetimibe) is adequately identified, and statistical software is named.

Evidence

paraphrase[Methods, Randomisation and masking]

“obicetrapib 10 mg plus ezetimibe 10 mg FDC, obicetrapib 10 mg monotherapy, ezetimibe 10 mg monotherapy, or matching placebo”

“Statistical analyses were performed using SAS version 9.4.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (obicetrapib and ezetimibe) is identified with dose and regimen, and statistical software is identified.

Evidence

paraphrase[Methods, Randomisation and masking]

“Participants were randomly assigned in a 1:1:1:1 ratio to receive once per day orally administered FDC of obicetrapib 10 mg plus ezetimibe 10 mg, obicetrapib 10 mg monotherapy, ezetimibe 10 mg monotherapy, or matching placebo.”

“Statistical analyses were performed using SAS version 9.4.”

Statistical analysisFind in source

The primary analysis used ANCOVA with baseline LDL as covariate. Exact p-values are reported for primary endpoints. Effect sizes with 95% CIs are reported. Missing data imputation is described. The statistical software is identified. Data presentation includes individual data points (waterfall plots) and per-group n. Mathematical plausibility checks were not applicable due to continuous outcomes and large N.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well reported, with exact p-values and confidence intervals.

Evidence

“An ANCOVA model with a fixed effect for the treatment group and a covariate of baseline LDL cholesterol was used to assess the primary efficacy parameter”

Statistical analysisFind in source

paraphrase[Results, paragraph 2]

“At day 84, the difference in the reduction of LDL cholesterol concentrations in the obicetrapib–ezetimibe FDC group was –48·6% (95% CI –58·3 to –38·9, p<0·0001)”

“Each vertical bar represents the percent change in LDL cholesterol measured by preparative ultracentrifugation for an individual patient in the treatment group from baseline to day 84”

Figure 3Find in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals for primary endpoints.

Evidence

paraphrase[Methods, Statistical analysis]

“An ANCOVA model with a fixed effect for the treatment group and a covariate of baseline LDL cholesterol was used to assess the primary efficacy parameter.”

paraphrase[Results, paragraph 3]

“At day 84, the difference in the reduction of LDL cholesterol concentrations in the obicetrapib–ezetimibe FDC group was –48·6% (95% CI –58·3 to –38·9, p<0·0001) compared with the placebo treatment group.”

“Primary endpoint: least-squares mean percent difference in LDL cholesterol reduction (95% CI) Obicetrapib plus ezetimibe FDC NA –16·8 (–26·4 to –7·1) –27·9 (–37·5 to –18·4) –48·6 (–58·3 to –38·9)”

Table 2Find in source

The data sharing statement says there is no plan to share individual participant data due to consent limitations, which is acceptable for patient data, but it does not provide a mechanism for data access requests. No code is shared, but the analysis used standard statistical software (SAS), so code sharing may not be applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Data availability statement is present but vague, and no code is shared.

Evidence

“There is no plan to share individual participant data due to limitations of patient consent.”

Data availabilityFind in source

WARNReviewer 2· 80% conf

Data availability statement is present but vague, and no code is shared.

Evidence

“There is no plan to share individual participant data due to limitations of patient consent.”

Data availabilityFind in source

The trial is registered (NCT06005597). Methods are detailed. Limitations are discussed. Conclusions are proportional to the evidence. Funding and conflicts of interest are declared. The paper does not explicitly reference a reporting guideline (e.g., CONSORT), but the trial profile is provided.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are complete, limitations are discussed, and conclusions are proportional.

Evidence

“The trial is registered with ClinicalTrials.gov (NCT06005597) and is completed.”

MethodsFind in source

“The trial has several limitations. First, most participants were White; however, the trial enrolled 14% Black or African American participants as well as 43% women, who have traditionally been under-represented in clinical trials. Second, the follow-up period was only 84 days”

Discussion ¶8Find in source

“ASt, DK, ALN, JK, MDa, and MDi are employees of NewAmsterdam Pharma.”

Declaration of interestsFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are complete, limitations are discussed, and funding/COI are disclosed.

Evidence

“The trial is registered with ClinicalTrials.gov (NCT06005597) and is completed.”

MethodsFind in source

Discussion ¶7Find in source

“Funding NewAmsterdam Pharma.”

FundingFind in source

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 33 references by DOI: 1 verified — 32 no DOI (shown, not verified).

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported; an informed reader should weigh the minor data-sharing limitation and the small internal inconsistencies (CI sign in abstract, missing CONSORT reference) as minor issues that do not undermine the main conclusions. No erratum is warranted for the CI sign inconsistency, but the authors should consider clarifying the data availability mechanism and explicitly citing CONSORT in any future correspondence or revision.

1.
HIGHdata code
Revise the Data sharing statement to provide a concrete mechanism for accessing de-identified aggregate data, e.g., 'De-identified aggregate data will be made available upon reasonable request to the corresponding author, subject to approval by the sponsor and a data sharing agreement.'
The current statement is vague and does not offer any avenue for data access, which is a common reviewer concern for clinical trials.
2.
HIGHreporting
Explicitly state adherence to CONSORT reporting guidelines in the Methods or Acknowledgments, and consider including a CONSORT flow diagram in the main text.
The paper follows a CONSORT-like structure but does not explicitly reference the guideline, which is a minor reporting gap that reviewers may flag.
3.
MEDIUMcopyedit
Fix the typo 'ASVCD' to 'ASCVD' in the Abstract (Methods section).
The copyedit pass flagged this typo, which could undermine the paper's professionalism.
4.
MEDIUMcopyedit
Ensure consistent ordering of confidence interval bounds across all endpoints; specifically, the abstract reports the obicetrapib monotherapy vs placebo CI as (22·1 to 41·6) while the results section reports it as (–41·6 to –22·1).
The sign inconsistency in the CI is confusing and could be misinterpreted; standardize to low-to-high ordering with consistent signs.
5.
MEDIUMreporting
Clarify the role of the sponsor in data analysis and publication to address potential bias.
The sponsor is the funder and several authors are employees; a clear statement on sponsor involvement in analysis and publication is important for transparency.
6.
LOWdata code
Consider depositing de-identified aggregate data or summary statistics in a public repository (e.g., Zenodo) to enhance transparency.
Even if individual participant data cannot be shared, aggregate data would improve reproducibility and public trust.
7.
LOWdata code
If any custom analysis code was used, share it in a public repository (e.g., GitHub) with a DOI.
Sharing code, even for standard analyses, can enhance reproducibility and is increasingly expected.
8.
LOWcopyedit
Check consistency of the LDL conversion factor notation (38·67 mg/dL = 1 mmol/L) across all tables and text.
The copyedit pass noted potential inconsistency in conversion factor notation; ensure it is uniform.

Full text (58,792 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.

Sarraju A, Brennan D, Hayden K, Stronczek A, Goldberg AC, Michos ED, McGuire DK, Mason D, Tercek G, Nicholls SJ, Kling D, Neild AL, Kastelein J, Davidson M, Ditmarsch M, Nissen SE

Read full text

DOI

10.1016/S0140-6736(25)00721-4

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/7dafeffa-3328-45df-a199-bb707f5f8678" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/7dafeffa-3328-45df-a199-bb707f5f8678/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

4e44c43e2290da7abfb40178a7413165bcb6bac820c4bf1f10aedb05e5cd16d7

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 17 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on LDL cholesterol reduction, a surrogate biomarker for cardiovascular outcomes. Although the paper cites prior evidence linking LDL cholesterol reduction to reduced ASCVD events, it does not demonstrate target engagement (e.g., PK/PD) at the tested dose in this trial, and the surrogate-to-clinical-outcome link is not validated within this study. The claim of clinical benefit is inferred from LDL lowering.
“Combination therapy of obicetrapib and ezetimibe significantly reduced LDL cholesterol. This oral, single-pill therapy could improve LDL cholesterol management in patients with pre-existing or high risk for ASCVD.”
Find in source

Findings by category

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 8 tests: 8 consistent, 0 inconsistent; 8 via agent-written checks.

Overstated conclusions

1 finding · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

1 finding · worst low

Other integrity concernAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

“Clinical trials of several classes of LDL cholesterol-lowering drugs have shown consistent reductions in major adverse cardiovascular events.”

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 2]

paraphrase[Discussion, paragraph 4]

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 1]

“A large meta-analysis of statin drug trials demonstrated a 22% reduction in cardiovascular events for each 1 mmol/L (38·7 mg/dL) reduction in LDL cholesterol concentration.”

paraphrase[Introduction, paragraph 2]

Research in contextFind in source

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomisation and masking]

“Randomisation was computer-generated by a contract research organisation through the ClinTrak Interactive Response Technology system. A permuted block design was used (block size of 8).”

“Masking was achieved by the use of identical tablets and capsules such that study investigators and participants could not determine whether they contained active drug or placebo.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomisation and masking]

“Randomisation was computer-generated by a contract research organisation through the ClinTrak Interactive Response Technology system. A permuted block design was used (block size of 8).”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline characteristics are well reported, including sex, age, and health status.

Evidence

paraphrase[Results, paragraph 1]

“The median age of participants was 68·0 years (IQR 62·0–73·0), 79 (19%) were at least 75 years of age, 177 (43%) were female”

paraphrase[Table 1]

“Race: White 86 (84%) ... Black or African American 14 (14%) ... Ethnicity: Hispanic or Latino 4 (4%)”

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, race, and comorbidities.

Evidence

paraphrase[Table 1]

“Median age (IQR), years 68·0 (63·0–72·0) 67·0 (61·0–74·0) 68·0 (64·0–73·0) 67·5 (62·0–72·0) Sex Female 48 (47%) 33 (32%) 45 (45%) 51 (50%)”

“Race White 86 (84%) 85 (83%) 82 (81%) 84 (82%) Black or African American 14 (14%) 15 (15%) 13 (13%) 17 (17%)”

Table 1Find in source

“History of ASCVD 72 (71%) 76 (75%) 67 (66%) 65 (64%)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval and informed consent are adequately reported.

Evidence

“The protocol and amendments were approved by a central ethics committee (Advarra) for all sites, with initial approval on Sept 28, 2023 (trial reference number Pro00074209).”

MethodsFind in source

“All participants provided written informed consent before undergoing any study procedures.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval and informed consent are clearly documented.

Evidence

“The protocol and amendments were approved by a central ethics committee (Advarra) for all sites, with initial approval on Sept 28, 2023 (trial reference number Pro00074209).”

MethodsFind in source

“All participants provided written informed consent before undergoing any study procedures.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (obicetrapib and ezetimibe) is adequately identified, and statistical software is named.

Evidence

paraphrase[Methods, Randomisation and masking]

“obicetrapib 10 mg plus ezetimibe 10 mg FDC, obicetrapib 10 mg monotherapy, ezetimibe 10 mg monotherapy, or matching placebo”

“Statistical analyses were performed using SAS version 9.4.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (obicetrapib and ezetimibe) is identified with dose and regimen, and statistical software is identified.

Evidence

paraphrase[Methods, Randomisation and masking]

“Statistical analyses were performed using SAS version 9.4.”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well reported, with exact p-values and confidence intervals.

Evidence

“An ANCOVA model with a fixed effect for the treatment group and a covariate of baseline LDL cholesterol was used to assess the primary efficacy parameter”

Statistical analysisFind in source

paraphrase[Results, paragraph 2]

“At day 84, the difference in the reduction of LDL cholesterol concentrations in the obicetrapib–ezetimibe FDC group was –48·6% (95% CI –58·3 to –38·9, p<0·0001)”

“Each vertical bar represents the percent change in LDL cholesterol measured by preparative ultracentrifugation for an individual patient in the treatment group from baseline to day 84”

Figure 3Find in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals for primary endpoints.

Evidence

paraphrase[Methods, Statistical analysis]

“An ANCOVA model with a fixed effect for the treatment group and a covariate of baseline LDL cholesterol was used to assess the primary efficacy parameter.”

paraphrase[Results, paragraph 3]

Table 2Find in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Data availability statement is present but vague, and no code is shared.

Evidence

“There is no plan to share individual participant data due to limitations of patient consent.”

Data availabilityFind in source

WARNReviewer 2· 80% conf

Data availability statement is present but vague, and no code is shared.

Evidence

“There is no plan to share individual participant data due to limitations of patient consent.”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are complete, limitations are discussed, and conclusions are proportional.

Evidence

“The trial is registered with ClinicalTrials.gov (NCT06005597) and is completed.”

MethodsFind in source

Discussion ¶8Find in source

“ASt, DK, ALN, JK, MDa, and MDi are employees of NewAmsterdam Pharma.”

Declaration of interestsFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are complete, limitations are discussed, and funding/COI are disclosed.

Evidence

“The trial is registered with ClinicalTrials.gov (NCT06005597) and is completed.”

MethodsFind in source

Discussion ¶7Find in source

“Funding NewAmsterdam Pharma.”

FundingFind in source

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 33 references by DOI: 1 verified — 32 no DOI (shown, not verified).

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
Revise the Data sharing statement to provide a concrete mechanism for accessing de-identified aggregate data, e.g., 'De-identified aggregate data will be made available upon reasonable request to the corresponding author, subject to approval by the sponsor and a data sharing agreement.'
The current statement is vague and does not offer any avenue for data access, which is a common reviewer concern for clinical trials.
2.
HIGHreporting
Explicitly state adherence to CONSORT reporting guidelines in the Methods or Acknowledgments, and consider including a CONSORT flow diagram in the main text.
The paper follows a CONSORT-like structure but does not explicitly reference the guideline, which is a minor reporting gap that reviewers may flag.
3.
MEDIUMcopyedit
Fix the typo 'ASVCD' to 'ASCVD' in the Abstract (Methods section).
The copyedit pass flagged this typo, which could undermine the paper's professionalism.
4.
MEDIUMcopyedit
Ensure consistent ordering of confidence interval bounds across all endpoints; specifically, the abstract reports the obicetrapib monotherapy vs placebo CI as (22·1 to 41·6) while the results section reports it as (–41·6 to –22·1).
The sign inconsistency in the CI is confusing and could be misinterpreted; standardize to low-to-high ordering with consistent signs.
5.
MEDIUMreporting
Clarify the role of the sponsor in data analysis and publication to address potential bias.
The sponsor is the funder and several authors are employees; a clear statement on sponsor involvement in analysis and publication is important for transparency.
6.
LOWdata code
Consider depositing de-identified aggregate data or summary statistics in a public repository (e.g., Zenodo) to enhance transparency.
Even if individual participant data cannot be shared, aggregate data would improve reproducibility and public trust.
7.
LOWdata code
If any custom analysis code was used, share it in a public repository (e.g., GitHub) with a DOI.
Sharing code, even for standard analyses, can enhance reproducibility and is increasingly expected.
8.
LOWcopyedit
Check consistency of the LDL conversion factor notation (38·67 mg/dL = 1 mmol/L) across all tables and text.
The copyedit pass noted potential inconsistency in conversion factor notation; ensure it is uniform.

Full text (58,792 chars)Analyzed: Aug 15, 2026